Hydroxyurea decreases gemcitabine resistance in pancreatic carcinoma cells with highly expressed ribonucleotide reductase

Pancreas

Volumn 41, Issue 1, 2012, Pages 107-113

  Funamizu, Naotake ^a   Kamata, Yuko ^b   Misawa, Takeyuki ^a   Uwagawa, Tadashi ^a   Lacy, Curtis Ray ^a   Yanaga, Katsuhiko ^a   Manome, Yoshinobu ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

chemoresistance; gemcitabine; mesenchymal phenotype; pancreatic carcinoma; ribonucleotide reductase

Indexed keywords

GEMCITABINE; HYDROXYUREA; RIBONUCLEOTIDE REDUCTASE; SMALL INTERFERING RNA;

ARTICLE; CANCER RESISTANCE; CARCINOMA CELL; CELL PROLIFERATION; CHEMOSENSITIVITY; COLORIMETRY; CONTROLLED STUDY; DRUG METABOLISM; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; PANCREAS CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BLOTTING, WESTERN; CADHERINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; HYDROXYUREA; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBONUCLEOTIDE REDUCTASES; RNA INTERFERENCE; TRANSCRIPTION FACTORS; VIMENTIN;

EID: 84655169149     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e318224b5fb     Document Type: Article

References (40)

1. Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet. 2004;363: 1049-1057. (Pubitemid 38410779)
2. Garcia-Manteiga J, Molina-Arcas M, Casado FJ, et al. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2ï,2,-difluorodeoxycytidineYinduced ytotoxicity. Clin Cancer Res. 2003;9:5000-5008. (Pubitemid 37323307)
3. GioVannetti E, Del Tacca M, Mey V, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 2006;66:3928-3935.
4. Bergman AM, Eijk PP, Ruiz Van Haperen VW, et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res. 2005;65:9510-9516. (Pubitemid 41508021)
5. Nakahira S, Nakamori S, Tsujie M, et al. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer. 2003;120:1355-1363.
6. Rosell R, Danenberg KD, Alberola V, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/ cisplatinYtreated adVanced nonYsmall cell lung cancer patients. Clin Cancer Res. 2004;10:1318-1325. (Pubitemid 38365223)
7. Kroep JR, Loves WJ, Van Der Wilt CL, et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther. 2002;1:371-376.
8. Wang Z, Li Y, Kong D, et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009;69:2400-2407.
9. Arumugam T, Ramachandran V, Fournier KF, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009;69:5820-5828.
10. Ozols RF. Chemotherapy for ovarian cancer. Semin Oncol. 1999;26:34-40. (Pubitemid 30013261)
11. Hortobagyi GN. Developments in chemotherapy of breast cancer. Cancer. 2000;88:3073-3079. (Pubitemid 30413193)
12. RaghaVan D. AdVanced bladder and urothelial cancers. Eur J Cancer. 2000;36:1-6.
13. Blackstock AW, Lightfoot H, Case LD, et al. Tumor uptake and elimination of 2ï,2,-difluorodeoxy-cytidine (gemcitabine) after deoxycytidine kinase gene transfer correlation with in vivo tumor response. Clin Cancer Res. 2001;7:3263-3268. (Pubitemid 32963852)
14. Neff T, Blau CA. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp Hematol.1996;24:1340- 1346. (Pubitemid 26348932)
15. Olmeda D, Moreno-Bueno G, Flores JM, et al. SNAI1 is required for tumor growth and lymph node metastasis of human breast carcinoma MDA-MB-231 cells. Cancer Res. 2007;67:11721-11731.
16. Shah AN, Summy JM, Zhang J, et al. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol. 2007;14:3629-3637. (Pubitemid 350160137)
17. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442-454.
18. Funamizu N, Okamoto A, Kamata Y, et al. Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression ofdeoxycytidine kinase? Oncol Rep. 2010;23:471-475.
19. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159. (Pubitemid 17064313)
20. Galmarini CM, Clarke ML, Jordheim L, et al. Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC Pharmacol. 2004;24:4-8.
21. Smid K, Bergman AM, Eijk PP, et al. Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits. Nucleosides Nucleotides Nucleic Acids. 2006;25:1001-1007. (Pubitemid 44651837)
22. Mori R, Ishikawa T, Ichikawa Y. Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells. Oncol Rep. 2007;17:1201-1205.
23. Hubeek I, Stam RW, Peters GJ, et al. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer. 2005;93:1388-1394. (Pubitemid 41752866)
24. Rückert F, Joensson P, Saeger HD, et al. Functional analysis of LOXL2 in pancreatic carcinoma. Int J Colorectal Dis. 2010;25:303-311.
25. Novak A, Hsu SC, Leung-Hagesteijn C, et al. Cell adhesion and the integrin-linked kinase regulate the LEF-1 and A-catenin signalling pathways. Proc Natl Acad Sci U S A. 1998;95:4374-4379.
26. Janji B, Melchior C, Gouon V, et al. Autocrine TGF-AYregulated expression of adhesion receptors and integrin-linked kinase in HT-144 melanoma cells correlates with their metastatic phenotype. Int J Cancer. 1999;83:255-262. (Pubitemid 29449106)
27. Javle MM, Gibbs JF, Iwata KK, et al. Epithelial-mesenchymal transition (EMT) and activated extracellular signalYregulated kinase (p-Erk) in surgically resected pancreatic cancer. Ann Surg Oncol. 2007;14: 3527-3533. (Pubitemid 350160113)
28. Roman NO, Samulitis BK, Wisner L, et al. Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase. Cancer Chemother Pharmacol. 2011;183-192.
29. Rosell R, Danenberg KD, Alberola V, et al. Spanish Lung Cancer Group. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatinYtreated adVanced nonYsmall cell lung cancer patients. Clin Cancer Res. 2004;10:1318-1325. (Pubitemid 38365223)
30. Colucci G, Labianca R, Di Costanzo F, et al. Gruppo Oncologico Italia Meridionale (GOIM). Gruppo Italiano per lo Studio dei Carcinomi dellïApparato Digerente (GISCAD). Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with adVanced pancreatic cancer: the GIP-1 study. J Clin Oncol. 2010;28:1645-1651.
31. Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with adVanced pancreatic cancer. J Clin Oncol. 2009;27: 5513-5518.
32. Chawla SP, Chua VS, Fernandez L, et al. AdVanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer. Mol Ther. 2010;18:435-441.
33. Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 2009;27:2231-2237.
34. Poplin E, Feng Y, Berlin J, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27:3778-3785.
35. Kong R, Sun B, Jiang H, et al. Downregulation of nuclear factor-JB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer. Cancer Lett. 2010;291:90-98.
36. Ramachandran V, Arumugam T, Wang H, et al. Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival. Cancer Res. 2008;68:7811-7818.
37. Niu W, Liu X, Zhang Z, et al. Effects of vA6 gene silencing by RNA interference in PANC-1 pancreatic carcinoma cells. Anticancer Res. 2010;30:135-142.
38. Reid G, Wallant NC, Patel R, et al. Potent subunit-specific effects on cell growth and drug sensitivity from optimised siRNA-mediated silencing of ribonucleotide reductase. J RNAi Gene Silencing. 2009;5:321-330.
39. Cronin M, Sangli C, Liu ML, et al. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem. 2007;53:1084-1091. (Pubitemid 46867525)
40. Russo A, Rizzo S, Bronte G, et al. The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway. Oncology. 2009;77:57-68.